The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

被引：0
|
作者：
He, Zhiyong
Lin, Jinghui
He, Yueming
Zhang, Jing
Yang, Dongyong
Qiu, Wenbin
Lai, Jinhuo
Chen, Xi
Fang, Wenzheng
Ye, Feng
Xu, Tianwen
Wu, Huita
Qiu, Dongfa
Chen, Wujin
Cai, Lifang
Chen, Shengchi
Lin, Qunying
Lin, Li
机构：
[1] Fujian Canc Hosp, Fuzhou, Peoples R China
[2] Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China
[3] Fujian Med Univ, Hosp Quanzhou Affiliated 1, Quanzhou, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Quanzhou, Peoples R China
[5] Fuding Hosp Fujian Prov, Fuding, Peoples R China
[6] Fujian Med Univ, Union Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[7] Fujian Med Univ, 900 Hosp, Joint Logist Team, Clin Med Coll, Fuzhou, Peoples R China
[8] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[9] Fujian Med Coll, Affiliated Hosp 2, Quanzhou, Peoples R China
[10] Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen, Peoples R China
[11] Fujian Med Univ, Sanming Hosp 1, Sanming, Peoples R China
[12] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[13] Fujian Med Univ, Affiliated Hosp, Putian City Hosp 1, Putian City, Peoples R China
[14] First Hosp Nanping, Nanping, Peoples R China
[15] Putian Univ, Affiliated Hosp, Putian, Peoples R China
[16] FuJian Med Univ, Zhangzhou Affiliated Hosp, Zhangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9030
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study
    Chen, K.
    Fan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S39 - S39
  • [32] Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Nakamura, Atsushi
    Sato, Yuki
    Azuma, Koichi
    Sakata, Shinya
    Tachihara, Motoko
    Ikeda, Satoshi
    Yokoyama, Toshihide
    Ito, Kentaro
    Yano, Yukihiro
    Matsumoto, Hirotaka
    Daga, Haruko
    Hata, Akito
    Sakai, Kazuko
    Chiba, Yasutaka
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2023, 24 (06) : 519 - +
  • [33] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [34] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
    Holleman, Marscha S.
    Al, Maiwenn J.
    Zaim, Remziye
    Groen, Harry J. M.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 153 - 164
  • [35] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
    Marscha S. Holleman
    Maiwenn J. Al
    Remziye Zaim
    Harry J. M. Groen
    Carin A. Uyl-de Groot
    The European Journal of Health Economics, 2020, 21 : 153 - 164
  • [36] Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)
    Hata, Akito
    Katakami, Nobuyuki
    Kaji, Reiko
    Yokoyama, Toshihide
    Kaneda, Toshihiko
    Tamiya, Motohiro
    Inoue, Takako
    Kimura, Hiromi
    Yano, Yukihiro
    Tamura, Daisuke
    Morita, Satoshi
    Negoro, Shunichi
    CANCER, 2018, 124 (19) : 3830 - 3838
  • [37] Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
    Jung, H. A.
    Park, S.
    Lee, S. -H.
    Ahn, J. S.
    Ahn, M. -J.
    Sun, J. -M.
    ESMO OPEN, 2023, 8 (06)
  • [38] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
    Chen, X.
    Shen, J.
    Li, X.
    Yang, S.
    Xia, B.
    Wang, B.
    Wang, J.
    Zheng, S.
    Zhao, P.
    Ma, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S877 - S877
  • [39] A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
    Chen, Hua-Jun
    Tu, Hai-Yan
    Hu, Yanping
    Fan, Yun
    Wu, Guowu
    Cang, Shundong
    Yang, Yi
    Yang, Nong
    Ma, Rui
    Jin, Gaowa
    Xu, Ximing
    Liu, Anwen
    Tang, Shubin
    Cheng, Ying
    Yu, Yan
    Xu, Chong-Rui
    Zhou, Qing
    Wu, Yi-Long
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [40] Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer
    Kim, Chul
    Liu, Stephen V.
    Subramaniam, Deepa Suresh
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345